Addex Therapeutics Ltd ADR (ADXN)
NASDAQ: ADXNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ADXN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.08M
- EPS (TTM)
- -$7.56
- Dividend yield
- None
- 52-week range
- 2.56 – 10.43
- Day range
- 3.24 – 3.53
- Volume / Avg
- 18.22K / 383.35K
- Beta
- —
- Shares outstanding
- 1.75M
- Next earnings
- Nov 23, 2026
52-week range
ADXN stock today
Addex Therapeutics (ADXN) closed at $3.47 on Nov 20, up 2.06% (+$0.07), versus the S&P 500's 3.70% decline. Trading was light, with 18.22K shares changing hands, about 5% of the average daily volume. Shares are 66.7% below their 52-week high of $10.43 and 35.5% above the 52-week low of $2.56, near the bottom of the past year's range.
Addex Therapeutics has posted a net loss over the last twelve months (EPS of -$7.56), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Nov 23 before the market opens.
Summary generated from market data by MetaCap's automated system. Methodology
About Addex Therapeutics
Company profileAddex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Timothy Mark Dyer
- Headquarters
- Geneva
- Employees
- 3
- Website
- addextherapeutics.com
Earnings
Earnings history- Next report
- Nov 23, 2026
ADXN news
All ADXN news- ADDEX THERAPEUTICS TO REPORT 2026 THIRD QUARTER FINANCIAL RESULTS AND HOST CONFERENCE CALL ON NOVEMBER 25, 2026GlobeNewswire
- Addex Therapeutics Ltd Spin-out Neurosterix Closes $105 Million Series B FinancingNasdaq
- Addex Spin-out Neurosterix Closes $105 Million Series B FinancingGlobeNewswire
- Addex Therapeutics Ltd Increases Issued Share Capital to Create Treasury SharesNasdaq
- ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARESGlobeNewswire
- Addex Spin-Out Neurosterix Takes NTX-253 Closer To Phase 2 Schizophrenia TrialNasdaqADXN, ET
- Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for SchizophreniaGlobeNewswire
Addex Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ENVBEnveric Biosciences Inc. | 1.35 | -4.26% | $6.04M | vs ADXN |
| XCURExicure Inc. | 0.9001 | -12.82% | $5.89M | vs ADXN |
| ACXPAcurx Pharmaceuticals Inc. | 1.04 | +0.97% | $6.30M | vs ADXN |
| KYNBKyntra Bio Inc. | 1.56 | -13.33% | $6.32M | vs ADXN |
| GTBPGT Biopharma Inc. | 2.96 | -6.92% | $6.33M | vs ADXN |
| FBLGFibroBiologics Inc. | 0.705 | -15.06% | $6.34M | vs ADXN |
| TPSTTempest Therapeutics Inc. | 0.287 | -6.18% | $5.74M | vs ADXN |
| LGVNLongeveron Inc. Class A | 1.66 | -8.79% | $5.60M | vs ADXN |
Indexes, lists and sector
Addex Therapeutics stock FAQ
What is Addex Therapeutics's stock price today?
ADXN last traded at $3.47 as of Nov 20, 4:00 PM EST, up 2.06% on the day. Prices are delayed at least 15 minutes.
When is Addex Therapeutics's next earnings date?
Addex Therapeutics is expected to report earnings on Monday, November 23, 2026.
Who is Addex Therapeutics's CEO?
Mr. Timothy Mark Dyer is the chief executive officer of Addex Therapeutics Ltd ADR, which has about 3 employees.
What is the ADXN 52-week high?
The 52-week high for ADXN is $10.43 and the 52-week low is $2.56. The stock is currently 66.7% below its high.